3 terminated. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Terminated 3 |
Follow Neoplasms, Multiple Primary: new trials by email Literature Review of Neoplasms, Multiple Primary trials Research Report on Neoplasms, Multiple Primary
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex Sirolimus 0.2%, Sirolimus 0.4%, Placebo ointment - Angiofibroma of Face, Tuberous Sclerosis | Phase 2 | Terminated | Aucta Pharmaceuticals, Inc | 24 | 2017-04-12 | 2025-12-01 |
| Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockers Propranolol - Renal Angiomyolipomas, Tuberous Sclerosis | Phase 2 | Terminated | University Hospital, Bordeaux | 2 | 2015-05-22 | 2026-06-24 |
| A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors pertuzumab, erlotinib - Neuroendocrine Tumors, Carcinoid Tumors | Phase 2 | Terminated | Pamela L. Kunz | 4 | 2009-03-01 | 2017-03-03 |
Tuberous Sclerosis (2) · Adrenal Gland Neoplasms (1) · Carcinoid Tumor (1) · Erythema (1) · Exanthema (1) · Facies (1) · Fibroma (1) · Multiple Endocrine Neoplasia (1) · Neuroblastoma (1) · Neuroendocrine Tumors (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Genetic Diseases, Inborn (3) · Neoplasms (3) · Neoplastic Syndromes, Hereditary (3) · Congenital Abnormalities (2) · Hamartoma (2) · Heredodegenerative Disorders, Nervous System (2) · Malformations of Cortical Development (2) · Malformations of Cortical Development, Group I (2) · Neoplasms by Histologic Type (2) · Nervous System Diseases (2) · Nervous System Malformations (2) · Neurocutaneous Syndromes (2) · Neurodegenerative Diseases (2)
(18F)GTP1 (1) · Erlotinib Hydrochloride (1) · Propranolol (1) · Sirolimus (1) · pertuzumab (1)
Aucta Pharmaceuticals, Inc (1) · Pamela L. Kunz (1) · University Hospital, Bordeaux (1)
United States (2) · China (1) · France (1)
Pamela Kunz (1) · Shoufeng Li, Ph.D (1)